Facebook
Linkedin
Twitter
Industries
Aerospace
Agritech
Automotive
BFSI
Biotechnology
Chemicals
Defence Technology
Energy, Power and Sustainability
Food & Beverage
Healthcare
Information Technology
MarTech
Internet Of Things (IOT)
Logistics and Supply Chain
Materials
Medical Devices
Retail
Semiconductor & Electronics
Smart Lighting
Latest News
Interviews
Insights
Guest Post
Staff Writer
Featured Article
Resource Center
Resources
Press Releases
Search
Sunday, December 22, 2024
Facebook
Linkedin
Twitter
Sign in
Welcome! Log into your account
your username
your password
Forgot your password? Get help
Privacy Policy
Password recovery
Recover your password
your email
A password will be e-mailed to you.
ReadMagazine
Industries
All
Aerospace
Agritech
Automotive
BFSI
Biotechnology
Chemicals
Defence Technology
Energy, Power and Sustainability
Food & Beverage
Healthcare
Information Technology
MarTech
Internet Of Things (IOT)
Logistics and Supply Chain
Materials
Medical Devices
Retail
Semiconductor & Electronics
Smart Lighting
Read Magazine’s Weekly News Roundup With Wherobots, Helm.ai, Adyen, Palantir, And…
Saia Partners with Tesla to Launch Two Electric Semis
Excelsior Energy Secures 7.5 GWh BESS Deal with LG Vertech
3M and US Conec Partner on Beam Optical Tech for Data…
Latest News
Interviews
Insights
Guest Post
Staff Writer
Featured Article
Resource Center
Resources
Press Releases
Home
Tags
Immunotherapy Regimen
Immunotherapy Regimen
Biotechnology
IMFINZI Plus Chemotherapy Approved in the US as the First Immunotherapy Regimen
Business Wire
-
September 6, 2022
AstraZeneca’s IMFINZI (durvalumab) has been approved in the US for the treatment of adult patients with locally advanced or metastatic biliary tract cancer (BTC)...
0
Fans
Like
3,912
Followers
Follow
0
Subscribers
Subscribe
Hot Topics
Read Magazine’s Weekly News Roundup With Wherobots, Helm.ai, Adyen, Palantir, And More!
Saia Partners with Tesla to Launch Two Electric Semis
Excelsior Energy Secures 7.5 GWh BESS Deal with LG Vertech
Load more
